In patients with acute heart failure, the initial application of arterial vasodilators can reduce the working pressure of the heart wall, reduce the potential myocardial injury, and thus benefit the recovery of patients. Researchers recently studied the use of uraritide in patients with acute heart failure.
In a double-blind trial, researchers enrolled 2157 patients with acute heart failure who were randomly assigned to receive either 15ng/kg/min of uraritide or placebo intravenously for two days. The initial clinical review was performed at a median time of 6 hours after the initiation of treatment. The key endpoint was a hierarchical composite endpoint that negatively correlated with cardiovascular death at 15-month follow-up and the initial 2-day clinical review.
Cardiovascular deaths occurred in 236 patients in the uralaritide group and 225 patients in the placebo group (21.7%vs21.0%, 95%CI0.85-1.25, P=0.75). In the intention-to-treat analysis, there were no significant hierarchical composite outcome differences between groups. However, there was no significant difference in the change of cardiac troponin T level between the two groups during the whole infusion.
The results showed that the use of uraritide in patients with AHF resulted in excellent physiological effects, but did not harm the clinical complex terminal or reduce the long-term cardiovascular mortality in the short term.
Post time: Nov-29-2024